Bayer's Asundexian Demonstrated a Substantial, 26 Percent Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo
February 07, 2026
February 07, 2026
LEVERKUSEN, Germany, Feb. 7 -- Bayer, a pharmaceutical and life sciences company, issued the following news release:
* * *
Bayer's asundexian demonstrated a substantial, 26 percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient is . . .
* * *
Bayer's asundexian demonstrated a substantial, 26 percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo
In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient is . . .